Merck Stock: The Battle Among Weight-Loss Drugs Has A New Contender
Merck stock wavered Tuesday after unveiling new data for a potential competitor to weight-loss drugs from Novo Nordisk and Eli Lilly.
Source: investors.com
Stay updated with breaking news from Umer Raffat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck stock wavered Tuesday after unveiling new data for a potential competitor to weight-loss drugs from Novo Nordisk and Eli Lilly.
Indianapolis-based Elevance Health, which operates Anthem plans, said that in most cases, it won't cover Ozempic unless a patient is diagnosed with diabetes and has tried another medication to manage it, but physicians can still prescribe it.
US stock markets are wavering as politicians continue their talks about the debt ceiling problem.